• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    8.371 +0.231 (+2.84%)
    Streaming Delayed Price Updated: 1:18 PM EDT, Sep 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Iovance Biotherapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    23 24 Next >
    News headline image
    Analyst Expectations For Iovance Biotherapeutics's Future ↗
     
    Via Benzinga
    News headline image
    Health In Tech (NASDAQ: HIT) Posts Blowout Q2, Stock Responds – HIT, SNYR, PNPN.V/PNPNF in Breakout Zone; See More to Watch Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗
    The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
    Via Investor's Business Daily
    News headline image
    D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside ↗
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Iovance Biotheapeutics, Inc. (IOVA) to Inquire About Their Rights in Class Action Lawsuit
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi &amp; Korsinsky
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    IOVA Deadline: Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    July 14, 2025 Deadline: Contact Levi &amp; Korsinsky to Join Class Action Suit Against IOVA
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Investors in Iovance Biotherapeutics, Inc. Should Contact Levi &amp; Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    IOVA LAWSUIT ALERT: Levi &amp; Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    23 24 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.